• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

    5/13/25 7:00:00 AM ET
    $ALT
    $HTGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance
    Get the next $ALT alert in real time by email

    GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility, with a $15 million tranche funded at closing. Additional tranches will become available upon achievement of certain clinical and financial milestones aligned with the Company's pemvidutide development plans and financing needs.

    Access to this additional capital strengthens Altimmune's balance sheet, which included $150 million in cash and cash equivalents as of March 31, 2025, and will support the ongoing development of pemvidutide, Altimmune's novel GLP-1/glucagon dual receptor agonist. Pemvidutide is currently being studied in IMPACT, a Phase 2b trial in metabolic dysfunction-associated steatohepatitis (MASH), with top-line data expected in Q2 2025. In addition, Phase 2 trials evaluating pemvidutide in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) are expected to be initiated in the second and third quarters of 2025, respectively.

    Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune said, "We are excited to partner with Hercules, which has a strong history of funding innovative biopharmaceutical companies. We look forward to working with the Hercules team to maximize the potential of pemvidutide in liver and cardiometabolic indications. With our existing cash on hand, we expect this credit facility to significantly extend our cash runway at flexible, attractive terms."

    "Hercules is thrilled to support Altimmune as it develops pemvidutide as a potential therapy for the treatment of MASH, AUD and ALD," said Adam Soller, Managing Director at Hercules Capital. "We look forward to the upcoming data release from the IMPACT trial and serving as a long-term capital partner to Altimmune through its next chapter of clinical development."

    Under the terms of the agreement, $15 million will be drawn at closing. An additional $25 million is available in 2025 at Altimmune's option, subject to certain clinical and financial milestones. The remaining $60 million is available beginning in 2026, with $15 million subject to the achievement of certain clinical and financial milestones and up to $45 million available subject to the approval of Hercules. The facility is structured as interest only for the first 24 months, extendable up to 42 months on achievement of milestones. The loan matures 48 months from closing, and no warrants are included in the agreement.

    About Altimmune

    Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). For more information, please visit www.altimmune.com.

    Follow @Altimmune, Inc. on LinkedIn

    Follow @AltimmuneInc on X

    Company Contact:

    Greg Weaver

    Chief Financial Officer

    Phone: 240-654-1450

    [email protected]

    Investor Contact:

    Lee Roth

    Burns McClellan

    Phone: 646-382-3403

    [email protected]

    Media Contact:

    Jake Robison

    Inizio Evoke, Biotech

    Phone: 619-849-5383

    [email protected]

    This press release was published by a CLEAR® Verified individual.



    Primary Logo

    Get the next $ALT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALT
    $HTGC

    CompanyDatePrice TargetRatingAnalyst
    Altimmune Inc.
    $ALT
    2/28/2025Mkt Perform
    William Blair
    Altimmune Inc.
    $ALT
    1/8/2025$18.00Buy
    Stifel
    Hercules Capital Inc.
    $HTGC
    12/12/2024$19.50 → $21.50Mkt Perform → Outperform
    Keefe Bruyette
    Altimmune Inc.
    $ALT
    11/12/2024$26.00Buy
    UBS
    Altimmune Inc.
    $ALT
    4/29/2024Buy → Neutral
    Guggenheim
    Altimmune Inc.
    $ALT
    1/24/2024$13.00Neutral
    Goldman
    Hercules Capital Inc.
    $HTGC
    1/16/2024$17.00 → $17.50Buy → Neutral
    Compass Point
    Hercules Capital Inc.
    $HTGC
    11/21/2023$17.00Neutral
    UBS
    More analyst ratings

    $ALT
    $HTGC
    SEC Filings

    See more
    • Altimmune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Altimmune, Inc. (0001326190) (Filer)

      6/26/25 7:30:26 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Hercules Capital Inc.

      8-K - Hercules Capital, Inc. (0001280784) (Filer)

      6/20/25 4:17:16 PM ET
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Hercules Capital, Inc. (0001280784) (Filer)

      6/16/25 5:23:36 PM ET
      $HTGC
      Investment Managers
      Finance

    $ALT
    $HTGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hercules Capital Receives Affirmed BBB- Investment Grade Corporate and Unsecured Credit Rating from Fitch Ratings, Inc.

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Fitch Ratings, Inc. ("Fitch") has affirmed Hercules' investment grade corporate and unsecured credit rating of BBB- with a stable outlook, as well as its underlying analysis. "We are very pleased that Fitch has affirmed our BBB- investment grade corporate and unsecured credit rating," stated Seth Meyer, chief financial officer of Hercules. "This rating reflects the scale of our institutionalized lend

      7/1/25 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

      - $100 million funded upfront; additional $175 million tied to milestones provides strategic flexibility through key inflection points - WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced it has entered into a $275 million non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. The transaction strengthens the company's balance sheet as it advances DYNE-101 and DYNE-251

      6/30/25 4:01:00 PM ET
      $DYN
      $HTGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance
    • Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

      First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 2

      6/26/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    $HTGC
    Leadership Updates

    Live Leadership Updates

    See more
    • Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

      Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career Mr. Durso led biopharmaceutical company focused on liver disease as former CEO of Intercept Pharmaceuticals, previously oversaw multiple blockbuster franchises including cardiovascular and diabetes during 22-year tenure at Sanofi GAITHERSBURG, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri Lawver and Jerry Durso. "We are thrilled

      2/25/25 7:30:00 AM ET
      $ALT
      $DXCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Revelation Partners Expands Team with Hire of Andrew Olson, Partner, Chief Financial Officer & Chief Operating Officer

      SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer

      11/29/23 1:01:00 PM ET
      $HTGC
      $TPVG
      Investment Managers
      Finance
      Other Consumer Services
      Consumer Discretionary
    • Hercules Capital Announces the Appointment of Mr. Nikos Theodosopoulos to Its Board of Directors

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc

      9/25/23 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance

    $ALT
    $HTGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Altimmune

      William Blair initiated coverage of Altimmune with a rating of Mkt Perform

      2/28/25 7:17:56 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Altimmune with a new price target

      Stifel initiated coverage of Altimmune with a rating of Buy and set a new price target of $18.00

      1/8/25 7:32:53 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hercules Capital upgraded by Keefe Bruyette with a new price target

      Keefe Bruyette upgraded Hercules Capital from Mkt Perform to Outperform and set a new price target of $21.50 from $19.50 previously

      12/12/24 8:09:58 AM ET
      $HTGC
      Investment Managers
      Finance

    $ALT
    $HTGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Loo Wade was granted 9,328 shares and returned 5,999 shares to the company, decreasing direct ownership by 36% to 4,834 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      6/20/25 4:31:14 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Aguirre Deanne returned 5,999 shares to the company and was granted 9,328 shares, decreasing direct ownership by 34% to 5,067 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      6/20/25 4:30:56 PM ET
      $HTGC
      Investment Managers
      Finance
    • Chief Operating Officer Follmann Christian sold $7,043 worth of shares (395 units at $17.83) and bought $7,043 worth of shares (395 units at $17.83), increasing direct ownership by 0.22% to 121,212 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      6/5/25 6:38:34 PM ET
      $HTGC
      Investment Managers
      Finance

    $ALT
    $HTGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Follmann Christian sold $7,043 worth of shares (395 units at $17.83) and bought $7,043 worth of shares (395 units at $17.83), increasing direct ownership by 0.22% to 121,212 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      6/5/25 6:38:34 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Theodosopoulos Nikos bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 101% to 11,960 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:23 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Loo Wade bought $104,923 worth of shares (5,999 units at $17.49), returned 5,645 shares to the company and was granted 5,645 shares, increasing direct ownership by 5% to 7,504 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:04 PM ET
      $HTGC
      Investment Managers
      Finance

    $ALT
    $HTGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      11/14/24 11:58:56 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      10/17/24 11:16:51 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Altimmune Inc.

      SC 13G/A - Altimmune, Inc. (0001326190) (Subject)

      10/16/24 4:21:16 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALT
    $HTGC
    Financials

    Live finance-specific insights

    See more
    • Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

      First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks Weight loss of up to 6.2% at 24 weeks with no plateauing Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants Conference call to be held on June 2

      6/26/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

      GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, will host an investor webcast on Thursday, June 26, 2025 at 8:30 am E.T. to present topline 24 week data from its IMPACT Phase 2b trial evaluating pemvidutide in the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH). Conference Call InformationThe Company will host a conference call and webcast at 8:30 am E.T. on June 26, 2025. The call will include remarks from Altimmune management and Dr. Mazen Noureddin, Professor of Medicine at the H

      6/25/25 7:12:07 PM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Altimmune Announces First Quarter 2025 Financial Results and Business Update

      Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD), expected to initiate in Q2 and Q3 2025, respectively Cash, cash equivalents and short-term investments of $150 million as of March 31, 2025 $100 million credit facility secured with Hercules Capital, adding balance sheet strength and financial flexibility to support continued development of pemvidutide Webcast to be held today, May 13, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceuti

      5/13/25 7:00:00 AM ET
      $ALT
      Biotechnology: Pharmaceutical Preparations
      Health Care